Home
Contact Palatin
Site Map
.
.
.
.
.
.
Investor/Media Center
Overview
Press Releases
Event Calendar
Webcasts
SEC Filings
Analyst Coverage
Corporate Governance
Information Request
E-Mail Alerts
Investor Materials
Corporate Fact Sheet
Investor Materials
Management bios
For Institutional Investors and Media:
Carney Noensie
Burns McClellan
(212) 213-0006
cnoensie@burnsmc.com
Press Releases:
Feb-25-2010
PALATIN TECHNOLOGIES, INC. TO RAISE $2.6 MILLION DOLLARS IN REGISTERED DIRECT OFFERING
Feb-16-2010
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010
Feb-09-2010
Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
Dec-01-2009
Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
Nov-16-2009
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
Nov-12-2009
Palatin Technologies, Inc. To Report Fiscal Year 2010 First Quarter Results; Teleconference and Webcast to be held on November 16, 2009
Oct-28-2009
Palatin Technologies to Present at 8th Annual BIO Investor Forum
Sep-29-2009
Palatin Technologies to Receive $5 Million from AstraZeneca
Overview
Press Releases
Event Calendar
Webcasts
SEC Filings
Analyst Coverage
Corporate Governance
Information Request
E-Mail Alerts
Investor Materials
Overview
Executive Management
Board of Directors
Overview
Employee Benefits
Career Opportunities
Overview
Press Releases
Presentations
Events Calendar
Webcasts
Media Kit
Overview
PL-3994 for CHF
PL-3994 for Asthma
PL-3994 for Hypertension
Bremelanotide
PL-6983
Obesity